Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.
Approval Alert | Osimertinib in Advanced EGFR-Mutated NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population
2
FDA Grants Approval to Teclistamab Combo in RRMM
3
Why is the Incidence of Colorectal Cancer Rising in Young Patients?
4
Comparable Ipilimumab/Nivolumab Outcomes Observed in Older RCC Population
5